Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations

PURPOSE: Hairy cell leukemia (HCL) is a rare mature B cell leukemia. Purine analogs are the mainstay of treatment of HCL, but relapse after purine analog therapy is common. Outcomes of treatment of relapsed/refractory HCL typically diminish with each successive line of therapy. Moxetumomab pasudotox...

Descripción completa

Detalles Bibliográficos
Autores principales: Nobre, Carmen F., Newman, Matthew J., DeLisa, Anne, Newman, Pauline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647181/
https://www.ncbi.nlm.nih.gov/pubmed/31134324
http://dx.doi.org/10.1007/s00280-019-03875-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647181/
https://www.ncbi.nlm.nih.gov/pubmed/31134324
http://dx.doi.org/10.1007/s00280-019-03875-6

Ejemplares similares